Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Aura Energy #Aura to IPO Swedish Vanadium prospect


Avacta Share Chat (AVCT)



Share Price: 29.00Bid: 28.00Ask: 30.00Change: 0.00 (0.00%)No Movement on Avacta
Spread: 2.00Spread as %: 7.14%Open: 29.00High: 29.00Low: 29.00Yesterday’s Close: 29.00


Share Discussion for Avacta


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

woolfee
Posts: 640
Opinion:No Opinion
Price:101.00
all
22 Jun '16
those naughty 500 sells were put there to mask the big buyers at 103.475 imo
 
woolfee
Posts: 640
Opinion:No Opinion
Price:106.50
suki
22 Jun '16
yeah , patience required with pharmas , sold out of SUMM with 100% profits , and OXB for small loss , had I held ... guess you can figure it out for yourself
sukithedog
Posts: 1,092
Opinion:No Opinion
Price:106.50
RE: I am in
22 Jun '16
been in for a number of years , i feel this is a really exciting period for Avacta
woolfee
Posts: 640
Opinion:No Opinion
Price:106.00
I am in
22 Jun '16
surely zika virus is the menace of the moment , not n expert , but it does seem exciting tech , and at a discount to placing worth a punt - GLA
hopesprings
Posts: 113
Opinion:Strong Buy
Price:105.00
Brexit proof future
14 Jun '16
Avacta has amazing potential and its future income stream will be in dollars so it is a perfect share to buy
to wait out all the scaremongering of Cameron and Osborne who will soon fade into well deserved
oblivion.
Be happy
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:108.00
RE: Trader4Pay
2 Jun '16
Yep agreed s&p and ftse short term trades for income. AIM for long term growth opportunities. Good luck
Wisheyedbortum
Posts: 697
Opinion:No Opinion
Price:108.00
Trader4Pay
1 Jun '16
That's not the way to make money.
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:107.50
RE: Avacta.
27 May '16
Price will move north on any positive news before the profits come in. I was going to sell at 1.50 however it's a gamble although it would have made me a profit. Facts is I'm here for the long run and will just have to life with price fluctuations. Still in profit but I feel it won't go down much more. But never say never...
Wisheyedbortum
Posts: 697
Opinion:No Opinion
Price:107.50
Avacta.
25 May '16
The old adage that you should not fall in love with a share has been proven correct here, which is why I sold out at £1.19 having read that it will be 18 months to two years before Avacta becomes profitable. However, what a share this is going to be when the money starts rolling in, and at what point will the MMs realize the inevitable truth that it's going to be massive. Now comes the real difficulty, when to buy back in. At this juncture I'm thinking early, to spring 2017, but who knows.
sukithedog
Posts: 1,092
Opinion:No Opinion
Price:115.00
Grant awarded
24 Feb '16
Grant Funding Awarded
Wed, 24th Feb 2016 07:00
RNS Number : 8916P
Avacta Group PLC
24 February 2016

24 February 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta Awarded Grant Funding

Avacta to develop and potentially commercialise novel Affimer reagents to reduce use of animals in life sciences research

Potential to deliver substantial cost savings in global production of genetically engineered mice

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that it has been awarded a grant to work with the Mary Lyon Centre at MRC Harwell to develop novel Affimer reagents which could help reduce the use of animals in life sciences research. This has the potential to deliver substantial cost savings in the global production of genetically engineered mouse models, providing a significant commercial opportunity for the Company.

Genetically engineered mice are a widely used and essential tool in biomedical research and drug development. If the efficiency of the mice breeding programmes could be improved, the cost of production would be reduced and fewer animals would be required, providing ethical as well as commercial benefits.

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:

"We are grateful to NC3Rs for providing the funding that will allow us to develop Affimer inhibitors of inhibin, which we will provide to MRC Harwell for evaluation. If successful then there is a potentially very large global market for such Affimer reagents that will reduce the costs of production and the number of mice used each year in breeding programmes. We are delighted to be working with MRC Harwell on this project which could also open the way to applications in human IVF treatments."

Avacta has been awarded a CRACK IT Solutions technology partnering grant by NC3Rs, a UK-based scientific organisation dedicated to replacing, refining and reducing the use of animals in life sciences research. The grant provides funding for Avacta to develop Affimer inhibitors of a protein called inhibin. Inhibiting the action of this protein stimulates the production of greater numbers of embryos per mouse, a process called superovulation, which increases overall efficiency of a breeding programme. The Mary Lyon Centre at MRC Harwell, a world-leading centre for functional mouse genomics providing expertise, tools and facilities to generate mouse models of human disease, will evaluate the ability of the Affimer reagents to induce superovulation in mice.

A good inhibin inhibitor could reduce the number of mice needed for embryo production by 100,000 animals a year in the UK alone. When this is scaled up to the number of mice used in breeding programmes globally, there are substantial cost savings to be made in the production of genetically engineered mouse mode
TheAnswerIs42
Posts: 71
Opinion:No Opinion
Price:122.00
If only
26 Jan '16
They'd forgotten to change everyones' holdings as well as the price - now there's a nice thought. Aaah one day!
sukithedog
Posts: 1,092
Opinion:No Opinion
Price:122.00
RE: Rises leader board
26 Jan '16
very happy here
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:122.50
Rises leader board
26 Jan '16
See we are on top of the pile lol. Would be nice to see today's percentage increase as a real reality one day. Wishfull thinking springs to mind but you never know as the product may be completely revolutionary. I guess a buy out may happen before the real value can be realised.
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:122.50
Great news
26 Jan '16
Very happy with the outcome yesterday. This may well be the best performing share in my portfolio. I've been a holder for seven years so I guess I could have made money else where lol. This share has been a roller coaster. Good luck to all holders.
DoubleD7
Posts: 175
Opinion:No Opinion
Price:122.50
Share consolidation
26 Jan '16
Passed at the AGM yesterday and now effective. Here's hoping it leads to an upside, it should do
sukithedog
Posts: 1,092
Opinion:No Opinion
Price:1.25
RE: Latest
25 Jan '16
yep i like the update

more than happy to hold
DoubleD7
Posts: 175
Opinion:No Opinion
Price:1.25
Latest
25 Jan '16
The 3 year timescale is interesting as they're actually now planning and forecasting the future with more certainty. They have a number of commercial opportunities which should see revenues grow faster than they have. It's certainly been a bit of a slow burner but I suppose these pharma companies always are. The market seems to have liked what they've seen/heard though. I liked the part below from the RNS

The Company is engaged with a wide range of customers including large pharma and biotechs (including several of the top ten pharmaceutical companies), a number of diagnostics providers, several large bioprocessing and chromatography companies, and several EU, US and Asian academic and research institutes.

A key aspect of the business model is that a proportion of these custom Affimer projects and evaluations will lead to longer term commercial partnerships leading to payments for exclusivity, development milestones and longer term royalties on sales of Affimer containing products. The Company is negotiating a significant number of such commercial partnerships although these are taking longer than anticipated to complete.
DoubleD7
Posts: 175
Opinion:No Opinion
Price:1.25
Latest
25 Jan '16
Some interesting bits from the RNS, I'd be interested if anyone here went to the AGM

Following the Company's own progress in demonstrating the potential of Affimers as a therapeutic platform and the transformational therapeutic partnership that was established with Moderna Therapeutics in May 2015, Avacta successfully raised £21m net by way of a placing on 3 August 2015 with both existing and new institutional shareholders.

The proceeds will be used to accelerate the Group's in-house therapeutic programmes, focusing on oncology and blood clotting disorders; to support co-development partnerships; and to develop the therapeutic platform technology for key performance properties such as half-life extension, targeting and combination therapies. The primary strategic objective is to progress the first Affimer therapeutic into the clinic. This is expected to be achieved in approximately three years and this should be a significant value inflection point when it occurs.
DoubleD7
Posts: 175
Opinion:No Opinion
Price:1.25
Trading update
25 Jan '16
Cotrel joins Avacta from Abcam, where he held the role of Commercial Operations Director. Cotrel will lead the Group's commercial strategy and business development activities, and will drive the commercialisation of the Affimer technology as both research reagents and biotherapeutics.
DoubleD7
Posts: 175
Opinion:No Opinion
Price:1.25
Trading update
25 Jan '16
Avacta Group reports strong pre-clinical R&D progress for lead Affimer drug candidates against the PD-L1 immune checkpoint target, ahead of its annual general meeting today.

Other highlights:

· Key collaboration initiated with Dr Ramzi Ajjan at the Leeds General Infirmary to carry out pre-clinical characterisation of Affimer drug candidates that modulate blood clotting in pre-clinical models.

· Affimer technology evaluations started with 13 large pharma and biotechs, including four of the ten largest pharma companies, and with several large diagnostics providers and numerous other commercial partners and academic institutes.

· Dr Mike Owen, ex- SVP and global Head of Research of Biopharmaceuticals R&D at GlaxoSmithKline, appointed as non-Executive Director and Chair of the Scientific Advisory Board. · Appointment today of Dr Philippe Cotrel, ex-Commercial Operations Director at Abcam, as Chief Commercial Officer (see separate press release). · Appointment of Mr Tony Gardiner as Chief Financial Officer.

· Successful £21m fund raising via a placing of ordinary shares to support an Affimer therapeutics development programme.
· Avacta Animal Health trading at expected levels with further product launches planned for the second half of the financial year.
· Half year revenue of £1.0m (£0.7m FY15) made up of £0.3m from Avacta Life Sciences and £0.7m from Avacta Animal Health. The Company expects to announce its Interim Results for the six months ended 31 January 2016 on Monday 25 April 2016.

Chief executive Dr Alastair Smith said: "I am very pleased with progress in the period. It is good to see the number and quality of customers and partners that are evaluating the Affimer technology growing steadily as potential licensing and commercial relationships arising from these evaluations are key to maximising medium- and long-term value. We will continue to focus our resources on supporting these evaluation projects with partners who can deliver significant commercial opportunities in the longer term. The additions to the Senior Leadership Team and to the Board are particularly important and I am delighted with the recent appointments. During the coming months, we will update the market in detail on the progress of our two principal in-house therapeutic development programmes that are focused on immune checkpoint inhibitors for cancer therapies and on modulators of blood clotting. We also expect to establish new facilities in Cambridge for the expanding therapeutic development activity under Dr Amrik Basran, and later in the year to move into larger premises in Wetherby to support the Affimer reagents development and manufacturing operations."

Separately, the group announced the appointment of Philippe Cotrel as Chief Commercial Officer of Avacta, with immediate effect. Cotrel joins Avacta from Abcam, where he held the role of Commercial Operations Di
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:1.26
RE: T4P
16 Jan '16
WEB

I would agree with your thinking and I hope you're right. You would think the BOD have thought this through. We are over bought on the monthly chart which is a concern only news can keep us up at these levels and I believe past Q4 updates have been followed with positive news. Either way the co. looks like a great opportunity
Wisheyedbortum
Posts: 697
Opinion:No Opinion
Price:1.26
T4P
16 Jan '16
I am not very good with predictions, but I would guess that the consolidation will be followed by a business update which should give enough support to the £1.27 price tag of each share, otherwise it may tank and I am sure that Alastair Smith is far to shrewd to allow that to happen
Trader4Pay
Posts: 67
Opinion:No Opinion
Price:1.26
Large share purchaes
16 Jan '16
Market not great at the moment with more headwinds expected although I feel us authorities may step in as markets are at an inflection point. I have noticed some large buys re avacta but does not seem to be having an positive affect on the price. I assume these where investers hitting the offer as price suggest someone buying. I am talking about large amounts 50 / 75 k in pound value. Anyone with thought on this. I feel it strange for price to be drifting. We had a late trade after 4.30 ordinary trade worth over 50k. Should we expect a rise on Monday?
Wisheyedbortum
Posts: 697
Opinion:No Opinion
Price:1.32
Avacta
12 Jan '16
Very smart move by Avacta and I was expecting it at some time. this will de-risk the shares and move them into the sensible arena in preparation for the inevitable rise over the next three or four years. thanks for the info DD7.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.